Your search returned 5 results.

Results
	1.	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. [electronic resource] by Vazquez-Martin, A Oliveras-Ferraros, C Colomer, R Brunet, J Menendez, J A Producer: 20080721 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. [electronic resource] by Vazquez-Martin, A Oliveras-Ferraros, C Cufí, S Martin-Castillo, B Menendez, J A Producer: 20110111 In: Current molecular medicine vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. [electronic resource] by Vazquez-Martin, A Oliveras-Ferraros, C del Barco, S Martin-Castillo, B Menendez, J A Producer: 20090519 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. [electronic resource] by Martin-Castillo, B Dorca, J Vazquez-Martin, A Oliveras-Ferraros, C Lopez-Bonet, E Garcia, M Del Barco, S Menendez, J A Producer: 20100224 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. [electronic resource] by Oliveras-Ferraros, C Cufí, S Queralt, B Vazquez-Martin, A Martin-Castillo, B de Llorens, R Bosch-Barrera, J Brunet, J Menendez, J A Producer: 20120625 In: British journal of cancer vol. 106 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)